CNAT - Genfit Seeks $100 Million Global IPO
Quick Take
Genfit S.A. (GNFT) intends to raise $100 million in an IPO of ADSs representing ordinary shares, according to an F-1 registration statement.
The firm is developing treatment candidates for non-alcoholic steatohepatitis [NASH] conditions.
GNFT says it expects results from its Phase 3 trial for the treatment of adult NASH by the end of 2019.
Company & Technology
Loos, France-based Genfit was founded in 1999 to research treatments for non-alcoholic steatohepatitis, fibrosis, and auto-immune conditions.
Management is headed by Chairman, Co-founder and CEO Jean-Francois Mouney, who was previously founder of companies